Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kiadis Pharma has announced the clinical development collaboration for its lead product Atir with Stephan Mielke and Hermann Einsele from the Allogeneic Stem Cell Transplant Center, Division of Hematology and Oncology, Department of Internal Medicine II at the Julius-Maximilians University of Wurzburg, Germany.
Subscribe to our email newsletter
According to Dr Mielke selective allodepletion with Atir carries significant potential for improving the outcome of mismatched (haploidentical) transplants by allowing early immune reconstitution with less severe or no acute graft versus host disease (GvHD). Therefore, Dr Mielke and his team and Kiadis Pharma are planning to initiate a clinical Phase III study for mismatched (haploidentical) transplantations in blood cancer patients at the Julius-Maximilians University of Wurzburg.
Atir is designed to prevent life-threatening acute GvHD by eliminating the immune cells from the donor graft that otherwise attack the patient’s body.
Manja Bouman, CEO of Kiadis Pharma, said: “We are extremely pleased with this collaboration which shows the interest of leading transplantation physicians to continue working with our lead product Atir as well as to participate in setting up our next clinical study in Europe.”